Rezolute to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Rezolute, Inc. (Nasdaq: RZLT), a late-stage rare disease company focusing on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI), has announced its participation in two upcoming investor conferences. The company will attend the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024, and the Cantor Global Healthcare Conference from September 17-19, 2024.

During these events, Rezolute's management team will be available for one-on-one meetings with investors. Interested parties are encouraged to contact their H.C. Wainwright and Cantor representatives to schedule meetings. This participation provides an opportunity for investors to gain insights into Rezolute's progress in addressing rare diseases, particularly its work on hypoglycemia caused by hyperinsulinism.

News Market Reaction

+1.91%

1 alert

+1.91% News Effect

On the day this news was published, RZLT gained 1.91%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

REDWOOD CITY, Calif., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI), today announced that management will participate in the following investor conferences:

Event: H.C. Wainwright 26th Annual Global Investment Conference
Date: September 9-11, 2024

Event: Cantor Global Healthcare Conference
Date: September 17-19, 2024

Management will be participating in one-on-one investor meetings throughout the conferences. Investors interested in scheduling a meeting with the Rezolute management team should contact their H.C. Wainwright and Cantor representatives.

About Rezolute, Inc.

Rezolute is a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). The Company’s antibody therapy, RZ358 (ersodetug), is designed to treat all forms of HI and has shown substantial benefit in clinical trials and real-world use for the treatment of congenital hyperinsulinism (cHI) and tumor hyperinsulinism (tHI).

Contacts:

Rezolute, Inc.
Christen Baglaneas
cbaglaneas@rezolutebio.com
508-272-6717

LHA Investor Relations
Tirth T. Patel
tpatel@lhai.com
212-201-6614

FAQ

What investor conferences will Rezolute (RZLT) attend in September 2024?

Rezolute (RZLT) will attend the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024, and the Cantor Global Healthcare Conference from September 17-19, 2024.

How can investors meet with Rezolute (RZLT) management at the upcoming conferences?

Investors interested in meeting with Rezolute (RZLT) management should contact their H.C. Wainwright and Cantor representatives to schedule one-on-one meetings during the conferences.

What is Rezolute's (RZLT) primary focus in rare disease treatment?

Rezolute (RZLT) is focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI), a rare disease that affects blood sugar regulation.

When will the Cantor Global Healthcare Conference that Rezolute (RZLT) is attending take place?

The Cantor Global Healthcare Conference that Rezolute (RZLT) will attend is scheduled for September 17-19, 2024.